Bigenomic Sequencing Is Not the Clue to Increase the Diagnostic Yield in Mitochondrial Disorders
Himalayan Journal of Community Medicine and Public Health · 2020
DOI: 10.47310/hjcmph.2020.v01i01.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Himalayan Journal of Community Medicine and Public Health, 2020. Verfasst von Josef Finsterer.
Abstract (Originalsprache)
With interest we read the article by Kerr et al. about the diagnostic workup of 36 patients with confirmed mitochondrial disorder(MID) (MIDgroup) and 80 patients with suspected MID but yet unconfirmed diagnosis (NO-group) by means of next generation sequencing(NGS).[1] In the MID-group MID was diagnosed upon a traditional approach.[1] The authors found that bigenomic sequencing(BGS) confirmed the diagnosis in 13/36 MID-patients and detected new pathogenic variants in 3 other MID-patients. In the NO-group one new MID-patient was identified by NGS.[1] We have the following concerns.
Zitieren
APA
Finsterer, J. (2020). Bigenomic Sequencing Is Not the Clue to Increase the Diagnostic Yield in Mitochondrial Disorders. Himalayan Journal of Community Medicine and Public Health. https://doi.org/10.47310/hjcmph.2020.v01i01.022
Vancouver
Finsterer J. Bigenomic Sequencing Is Not the Clue to Increase the Diagnostic Yield in Mitochondrial Disorders. Himalayan Journal of Community Medicine and Public Health. 2020. doi:10.47310/hjcmph.2020.v01i01.022
BibTeX
@article{Finsterer2020,
author = {Finsterer, Josef},
title = {Bigenomic Sequencing Is Not the Clue to Increase the Diagnostic Yield in Mitochondrial Disorders},
journal = {Himalayan Journal of Community Medicine and Public Health},
year = {2020},
doi = {10.47310/hjcmph.2020.v01i01.022}
}
EUVIMED